Merck Sharp And Dohme

Drug firm Glenmark Pharmaceuticals on Thursday said it is evaluating legal options after the Delhi High Court restrained it from manufacturing and selling generic version of Merck Sharp and Dohme's anti-diabetes medicines Januvia and Janumet.

In a relief for US drug major Merck Sharp and Dohme (MSD), the Delhi High Court on Wednesday restrained Glenmark Pharmaceuticals from manufacturing and selling its anti-diabetes drugs Zita and Zita-Met, saying it has infringed patent of the American company.

In a relief for US drug major Merck Sharp and Dohme (MSD), Delhi High Court today restrained Indian firm Glenmark Pharmaceuticals from manufacturing and selling its anti-diabetes drugs Zita and Zita-Met, saying it has infringed patent of the American company.

The Supreme Court on Wednesday stayed till April 28 the order of Delhi High Court barring Indian pharmaceuticals major Glenmark from making, marketing or selling its anti-diabetes medicines in which US drug major Merck Sharp and Dohme (MSD) has claimed a patent right.

The Delhi High Court today posted April 12 as the date of hearing for an appeal filed by US pharmaceuticals major Merck Sharp and Dohme (MSD) against the single judge bench order refusing to restrain Indian firm Glenmark from manufacturing and selling anti-diabetes drugs Zita and Zita-Met.

US pharmaceutical major Merck Sharp and Dohme (MSD) has filed an appeal before the Delhi High Court challenging its single bench order refusing to grant interim relief to it on a patent row against Indian firm Glenmark Pharmaceuticals.

Drug firm Glenmark Pharmaceuticals on Thursday said it is evaluating legal options after the Delhi High Court restrained it from manufacturing and selling generic version of Merck Sharp and Dohme's anti-diabetes medicines Januvia and Janumet.

In a relief for US drug major Merck Sharp and Dohme (MSD), the Delhi High Court on Wednesday restrained Glenmark Pharmaceuticals from manufacturing and selling its anti-diabetes drugs Zita and Zita-Met, saying it has infringed patent of the American company.

In a relief for US drug major Merck Sharp and Dohme (MSD), Delhi High Court today restrained Indian firm Glenmark Pharmaceuticals from manufacturing and selling its anti-diabetes drugs Zita and Zita-Met, saying it has infringed patent of the American company.

The Supreme Court on Wednesday stayed till April 28 the order of Delhi High Court barring Indian pharmaceuticals major Glenmark from making, marketing or selling its anti-diabetes medicines in which US drug major Merck Sharp and Dohme (MSD) has claimed a patent right.

The Delhi High Court today posted April 12 as the date of hearing for an appeal filed by US pharmaceuticals major Merck Sharp and Dohme (MSD) against the single judge bench order refusing to restrain Indian firm Glenmark from manufacturing and selling anti-diabetes drugs Zita and Zita-Met.

US pharmaceutical major Merck Sharp and Dohme (MSD) has filed an appeal before the Delhi High Court challenging its single bench order refusing to grant interim relief to it on a patent row against Indian firm Glenmark Pharmaceuticals.